The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis
Open accessAbstract
BACKGROUND: Since 2009, IPF patients across Europe are recruited into the eurIPFreg, providing epidemiological data and biomaterials for translational research. METHODS: The registry data are based on patient and physician baseline and follow-up questionnaires, comprising 1700 parameters. The mid- to long-term objectives of the registry are to provide clues for a better understanding of IPF phenotype sub-clusters, triggering factors and aggravating conditions, regional and environmental characteristics, and of disease behavior and management. RESULTS: This paper describes baseline data of 525 IPF subjects recruited from 11/2009 until 10/2016. IPF patients had a mean age of 68.1 years, and seeked medical advice due to insidious dyspnea (90.1%), fatigue (69.2%), and dry coughing (53.2%). A surgical lung biopsy was performed in 32% in 2009, but in only 8% of the cases in 2016, possibly due to increased numbers of cryobiopsy. At the time of inclusion in the eurIPFreg, FVC was 68.4% ± 22.6% of predicted value, DLco ranged at 42.1% ± 17.8% of predicted value (mean value ± SD). Signs of pulmonary hypertension were found in 16.8%. Steroids, immunosuppressants and N-Acetylcysteine declined since 2009, and were replaced by antifibrotics, under which patients showed improved survival (p = 0.001). CONCLUSIONS: Our data provide important insights into baseline characteristics, diagnostic and management changes as well as outcome data in European IPF patients over time. TRIAL REGISTRATION: The eurIPFreg and eurIPFbank are listed in ClinicalTrials.gov( NCT02951416 ).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Compared with the recently published observational data from the EurIPF registry, patients in INSIGHTS-IPF were nearly identical in terms of total lung capacity (70.0%pred versus 71.2% pred), FVC (68.4% pred versus 68.3% pred) and FEV 1 (110% pred versus 111% pred), while D LCO was lower in our study (42.1% pred versus 37.8% pred) [18].”
From Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry (2020) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Coughing is a hallmark of IPF and represents one of the key symptoms of IPF patients in larger cohorts30.”
From Inhaled LTI-03 for idiopathic pulmonary fibrosis: a randomized dose escalation study (2026) · cites this paper as [30]
The cited source says what the claim attributes to it.
In the citing paper
“The analysis of this subset found that median survival on antifibrotic drugs was 123.1 months (censored cases inclusive, range 84-162 months), compared with a median survival of 68.3 months in patients treated with any other medication including immunosuppressive therapies (censored cases inclusive, range 54-83 months).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Prednisone, Azathioprine, and N -Acetylcysteine for Pulmonary Fibrosis
The Idiopathic Pulmonary Fibrosis Clinical Research Network (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113354 · Cited by 1,621
A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis
Ley, B., Ryerson, C. J., Vittinghoff, E., Ryu, J. H., Tomassetti, S., Lee, J. S., Poletti, V., Buccioli, M., Elicker, B. M., Jones, K. D., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-10-201205150-00004 · Cited by 1,308
Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper
Lynch, D. A., Sverzellati, N., Travis, W. D., Brown, K. K., Colby, T. V., Galvin, J. R., Goldin, J. G., Hansell, D. M., Inoue, Y., Johkoh, T., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30433-2 · Cited by 1,030 · cited 3×
“ing use of the WHO classification, complaints as well as report of co-morbidities [6].”
BackgroundMethodSelf-citationGlobal incidence and mortality of idiopathic pulmonary fibrosis: a systematic review
Hutchinson, J., Fogarty, A., Hubbard, R., & McKeever, T. (2015) · European Respiratory Journal · doi:10.1183/09031936.00185114 · Cited by 913
Raghu, G., Chen, S.-Y., Yeh, W.-S., Maroni, B., Li, Q., Lee, Y.-C., & Collard, H. R. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70101-8 · Cited by 716
The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622 · cited 1×
“In this regard, the diversity of this European IPF cohort may reflect not only the variety in natural course of the disease, but also changes in clinical management of the patients, especially when comparing our results to historic IPF cohorts [35].”
ResultIncidence and prevalence of idiopathic pulmonary fibrosis: review of the literature
Nalysnyk, L., Cid-Ruzafa, J., Rotella, P., & Esser, D. (2012) · European Respiratory Review · doi:10.1183/09059180.00002512 · Cited by 552
Cited by
Pathogenic Mechanisms Underlying Idiopathic Pulmonary Fibrosis
Moss, B. J., Ryter, S. W., & Rosas, I. O. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042320-030240 · Cited by 821
Wijsenbeek, M., Suzuki, A., & Maher, T. M. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01052-2 · Cited by 539
Troy, L. K., Grainge, C., Corte, T. J., Williamson, J. P., Vallely, M. P., Cooper, W. A., Mahar, A., Myers, J. L., Lai, S., Mulyadi, E., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30342-x · Cited by 396
Idiopathic pulmonary fibrosis: state of the art for 2023
Podolanczuk, A. J., Thomson, C. C., Remy-Jardin, M., Richeldi, L., Martinez, F. J., Kolb, M., & Raghu, G. (2023) · European Respiratory Journal · doi:10.1183/13993003.00957-2022 · Cited by 359
Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis
Kheirollahi, V., Wasnick, R. M., Biasin, V., Vazquez-Armendariz, A. I., Chu, X., Moiseenko, A., Weiss, A., Wilhelm, J., Zhang, J.-S., Kwapiszewska, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10839-0 · Cited by 293
Self-citation
Metadata
- Authors
- Guenther, A., Krauss, E., Tello, S., Wagner, J., Paul, B., Kuhn, S., Maurer, O., Heinemann, S., Costabel, U., Barbero, M. A. N., Müller, V., Bonniaud, P., Vancheri, C., Wells, A., Vasakova, M., Pesci, A., Sofia, M., Klepetko, W., Seeger, W., Drakopanagiotakis, F., & Crestani, B.
- Affiliations
- Justus-Liebig-Universität Gießen (DE)
- Ruhrlandklinik (DE)
- Hospital Clínico San Carlos (ES)
- Semmelweis University (HU)
- Université de Bourgogne (FR)
- University of Catania (IT)
- Royal Brompton Hospital (GB)
- Azienda Ospedaliera San Gerardo (IT)
- University of Naples Federico II (IT)
- Medical University of Vienna (AT)
- Goethe University Frankfurt (DE)
- Hôpital Bichat-Claude-Bernard (FR)
- ORCID
- Venue
- Respiratory Research
- Published
- 2018-07-28
- Volume
- 19
- Issue
- 1
- Pages
- 141-141
- ISSN
- 1465-9921 (ISSN-L)
- 1465-993X
- PMC
- PMC6064050
- OpenAlex
- W2883908584
- Cited by
- 268
- References
- 40
- Citations by year
- 2026: 21 · 2025: 17 · 2024: 18 · 2023: 38 · 2022: 42 · 2021: 48 · 2020: 41 · 2019: 40 · 2018: 3
- FWCI
- 24.84
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- Locations
- Respiratory Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- University writing server of the Justus Liebig University Giessen (Justus-Liebig-Universität Gießen) (submittedVersion, cc-by)
- Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) (submittedVersion, cc-by)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
- Universitätsbibliothek Gießen (cc-by)
- Funders
- European IPF Network FP7 Program
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Keywords
- idiopathic pulmonary fibrosis, patient registry, survival, antifibrotic therapy, lung function, pulmonary hypertension, corticosteroids, immunosuppressants, N-acetylcysteine, open lung biopsy, cryobiopsy, dyspnea
- MeSH terms
- Aged, Aged, 80 and over, Biopsy, Europe, Female, Humans, Longitudinal Studies, Lung, Male, Registries, Cohort Studies, Survival Rate, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1186/s12931-018-0845-5
- The paper
- Guenther, A., Krauss, E., Tello, S., Wagner, J., Paul, B., Kuhn, S., Maurer, O., Heinemann, S., Costabel, U., Barbero, M. A. N., Müller, V., Bonniaud, P., Vancheri, C., Wells, A., Vasakova, M., Pesci, A., Sofia, M., Klepetko, W., Seeger, W., . . . Crestani, B. (2018). The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis. Respiratory Research. https://doi.org/10.1186/s12931-018-0845-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.